Title of Invention

"A PROCESS OF MANUFACTURING CAMPTOTHECIN DERIVATIVES,"

Abstract

This invention relates to a process of manufacturing the compound of general formula 1 from the compound of general formula 2: wherein Y and Z are the same or different and each represents a hydrogen atom, an C1-C6 alkyl group, a C1-C3 hydroxyalkyl group, or a general protecting group of amine such as benzyloxycarbonyl, benzyl, etc.; R1is a hydrogen atom, an C1-C6 alkyl group, or a hydroxy group; R2 and R3 are the same or different and each represents a hydrogen atom or a hydroxy group, or they may be attached together to form a cyclic moiety, which is a methylenedioxy or an ethylenedioxy group; R4 is a hydrogen atom or an C1~C6 alkyl group; and R5, is hydrogen, hydroxy, tluoro, chloro, bromo. iodo or amine.

Full Text

Technical field This invention relates to a process of manufacturing a camptothecin derivative expressed by the following general formula 1, or a pharmaceutically acceptable salt thereof; (Formula Removed) wherein Y and Z are the same or different and each represents a hydrogen atom, an C1-C6 alkyl group, a C1-C3 hydroxyalkyl group, or a general protecting group of amine such as benzyloxycarbonyl, benzyl, etc.; R1 is a hydrogen atom, an C1-C6 alkyl group, or a hydroxy group; R2 and R3 are the same or different and each represents a hydrogen atom or a hydroxy group, or they may be attached together to form a cyclic moiety, which is a methylenedioxy or an ethylenedioxy group; R4 is a hydrogon atom or an C1 -C6 alkyl group; and R5 is hydrogen, hydroxy, tluoro, chloro, bromo, iodo or amine. Background Art Since the first isolation of camptotheein from the wood and bavk of Camptotheca acuminata by Wall and co-workers [M. E. Wall et al, J. Am. Chem. Sac, 88, 3888 (1966)], there had been many approaches to synthesize camptothecin. However, the development of camptothecin as an effective antineoplastic agent was unsuccessful due to its severe toxicity in the clinical trial in 1970. Thereafter, Liu et al reported in 1985 that camptothecin had a specific mode of action to inhibit lopoisomerase I. Thus, considerable interest has focused on this compound. Recently, various studies for the development of camptothecin derivatives have been proposed in order to reduce the toxicity of camptothecin and to further enhance its antineoplastic activities. Among these related studies, the clinical trial of CPT-11 (irinotecan) synthesized by Yakurt-Honsha Co. of Japan in 1986 showed that it exhibited excellent antineoplastic activities with less toxicity (Japanese Patent Laid Open Publication No. 64-61482) and followed by other pharmaceutical companies such as Smithkline Beecham (topotecan) and Glaxo (MDO-camptothecin and 9-amino camptothecin). Among them, CPT-11 and topotecan are launched. On the other hand, the present inventors have reported the 7-aminoethyl camptothecin derivatives and manufacturing process thereof through the total synthesis, which have strong antitumor activity, weak toxicity, and broad safe region, in Korean Patent Application No 95-269 and 96-248. the above invention produces camptothecin derivatives that ha\e strong antitumor activity. However, the procedure of manutacturing those is complex since the total synthesis is adopted and since intechlate material loed is a new one. Consequenly, there has been a strong need to develop a simple and convenient manutkcluring process ot camptothecin derivatives tor mass production. Accordingly, the inventors et al. have studied a convenient process by which camptothecin derivatives having excellent activities can be manufactured from a compound of general formula 2 such as (S)-7-methvl camptothecm [S.Savvada et al., Chem. Pharm. Bull., 39 (1991)2574-2580], Thus, the present invention has been completed Disclosure of the Invention A process of manulacturing camplothecm derivatives or a pharmaceutically acceptable salt thereof is described in more details as set forth hereunder, in accordance with the practice of this invention. This invention provides a process of manufacturing camptothecin derivatives of the compound of general formula 1 or a phamaceuncally acceptable salt thereof wherein the said process comprises: (Formula Removed) - reacting a compound of fonnula 2 with an amine or sail thereof and with a formaldehyde source ol the kind as herein described in the presence of an acid and a reaction solvent at a temperature ranging between 20-150° C. wherein Y and Z are the same or different and each represents a hydrogen atom, an C1~C3 alkyl group, a C1~C3 hydroxyalkyl group, or a general protecting group of amine such as benzyloxycarbonyl, benzyl, etc.; R1 is a hydrogen atom, an C1-C6 alkyl group, or a hydroxy group; R2and R3 are the same or different and each represents a hydrogen atom or a hydroxy group, or they may be attached together to form a cyclic moiety, which is a methylenedioxy or an ethylenedioxy group; R4 is a hydrogen atom or an C1~C6 alkyl group; and R5 is hydrogen, hydroxy, fluoro, chloro, bromo, iodo or amine. Preferably, R1R2R3.R4.R5and Y represent hydrogen atoms, and Z is isopropyl. Examples of the said formaldehyde source comprise formalin solution, paraformaldehyde, trioxane, dimethyl sulfoxide, etc.. Examples of the said amine comprise primary or secondary amines such as methyl amine, ethyl amine, propyl amine, isopropyl amine, butyl amine, pentyl amine, hexyl amine, benzyl amine, isopropylbenzyl amine, dimethyl amine, diethyl amine, benzyloxycarbonyl amine, hydroxymethyl amine, hydroxyethyl amine, hydroxypropyl amine and the like. In this reaction, examples of a reaction solvent comprise water, methanol, ethanol, dioxane, acetic acid, dimethylformamide, dimethyl sulfoxide and the like. Examples of the said acid comprise hydrochloric acid, sulfuric acid, acetic acid, phosphoric acid, p-toiuenesulfonic acid, methanesulfonic acid, trifluoromethanesulfonic acid, boron trifluoride, tin chloride and the like. And the reaction temperature is 20-150oC. According to the present invention, pharmaceutically acceptable salts of compounds represented with general formula 1 are inorganic acid salts such as hydrochloride, sulfate, phosphate, etc., or organic acid salts such as p-toluenesulfonate, acetate, methanesulfonate, trifluoromethanesulfonate, etc. This invention is explained in more detail by the following examples but the claims are not limited to these examples. Example 1: (S)-7-(2-(N-isopropylamino)ethyl] camptothecin hydrochloride (S)-7-methylcamptothecin (8 g, 0.0221 mol), isopropylamine (3.91 g, 0.0662 mol) and c-HCl (6.93 ml, 0.0684 mol) were added to dimethyl sulfoxide (80 ml). The reaction mixture was stirred at 140oC for one hour, and then cooled to room temperature. And the reaction solvent was removed by distillation under reduced pressure and the residue, so obtained, was purified by flash column chromatography with (methylene chloride: methanol = 10: 1) to give the desired product(6.75 g, 65 %) as pale yellow solid. 1H NMR (OMSO-d6. 400 MHz) δ : 9.29 (brs. 1H). 8.39) (d. 1H. J= 8.3Hz), 8.13 (d. 1H J-8.3HZ). 7.83 (t 1H. .1-7.1Hz), 7.72 (t. 1H. J=7.1Hz), 7.29 (s, 1H), 6.52 (s, 1H), 5.43 (s, 2H), 5.37 (s, 2H), 3.64-3.60 (m, 2H), 3.45-3.34 (m, 1H), 3.20-3.14 (m, 2H), 1.92-1.82 (m, 2H), 1.27 (d, 6H, J=6.4Hz), 0.87 (t, 3H, J=8.0Hz) Example 2: (S)-7-(2-(N-isopropylamino)ethyl] camptothecin hydrochloride (S)-7-methylcamptothecin (8 g, 0.0221 mol) and isopropylamine (3.91 g, 0.0662 mol) were added orderly in a mixed solution of formalin solution (37%, 9.73 ml, 0.12 mol) and c-HCl (6.93 ml, 0.0684 mol). The reaction mixture was stirred under reflux for 12 hours, and then cooled to room temperature. The reaction solvent was removed by distillation under reduced pressure and the residue, so obtained, was purified by flash column chromatography with (methylenechloride : methanol = 10 : 1) to give the desired product (6.23 g, 60 %) as pale yellow solid. The analysis data of the product is the same as example 1. Example 3: (S)-7-l2-(N-isopropylamino)ethyl] camptothecin hydrochloride (S)-7-methylcamptothecin (8 g, 0.0221 mol), isopropylamine (3.91 g, 0.0662 mol) and paraformaldehyde (5 g) were added orderly in a mixed solution of ethanol (30 ml), water (30 ml) and c-HCl (6.93 ml. 0.0684 mol). Then, the reaction mixture was stirred under reflux for 20 hours, and then cooled to room temperalure. The reaction solvent was removed by distillation under reduced pressure and the residue, so obtained, was purifled by flash column chromatography with (methylene chloride : methanol = 10 : 1) to give the desired product (6.35 g, 61.1 %) as pale yellow solid. The analysis data of the product is the same as example 1. Example 4: (S)-7-[2-(N-propylamino)ethyl]camptothecin hydrochloride The same procedure as in example 1 was applied to propylamine (496 mg, 0.0084 mol) and (S)-7-methyl camptothecin (1.005 g, 0.0028 mol) to give the desired product (677 mg, 52 %) as pale yellow solid. 1H-NMR (DMSO-d6) δ : 9.26 (brs, 1H), 8.43-7.7 (m, 4H), 7.3 (s, 1H), 6.48 (s, 1H), 5.42 (s, 2H), 5.29 (s, 2H), 3.64-3.37 (m, 2H), 3.2-3.11 (m,4H), 1.92-1.82 (m,2H), 1.27-1.11 (m, 8H), 0.88 (t, 3H, J=7.2Hz), 0.81 (t, 3H, J=7.3Hz) Example 5: (S)-7-(2-(N-isopropylamino)ethyl]-10,l1- methylenedioxycamptothecin hydrochloride The same procedure as in example 1 was applied to (S)-7-methyl-10,11-methylenedioxycamptothecin (1 g. 0.00248 mol) and isopropylamine (440 mg, 0.00744 mol) to give the desired product (540 mg, 48 %) as pale yellow solid. 1H NMR (DMSO-d6) δ ; 9.21 (brs, 1H). 7.6 (s. 1H), 7.4 (s, 1H), 7 21 (s. 1H), 6.28 (s, 2H), 5.4 (s, 2H), 5.32 (s. 2H). 3.64-3.60 (m. 2H). 3.45-3.34(m, 1H), 3.19-3.10 (m, 2H). 1.92 1.81 (m. 2H). 1.27 (d.6H. J-7.1HZ), 0.88(1, 3H,J=7.2Hz) Example 6: (S)-7-(2-(N-isopropylamino)ethyll-10,11- methlenedioxycamptothecin hydrochloride The same procedure as in example 2 was applied to (S)-7-methyl-10,1 l-methylenedioxycamptothecin (1 g, 0.00248 mol) and isopropylamine (440 mg, 0.00744 mol) to give the desired product (600 mg, 53 %) as pale yellow solid. The analysis data of the product is the same as example 5. Example 7: (S)-7-(2-(N-isopropylamino)ethyl]-10,11- methylenedioxycamptothecin hydrochloride The same procedure as in example 3 was applied to (S)-7-methyl-10,11-methylenedioxycamptothecin (1 g. 0.00248 mol) and isopropylamine (440 mg, 0.00744 mol) to give the desired product (565 mg, 51 %) as pale yellow solid. The analysis data of the product is the same as example 5. Example 8: (S)-7-|2-(N-isopropylamino)ethyll-10,11- cthylenedioxycamptothecin hydrochloride The same procedure as in example 1 was applied to (S)-7-methyl-l0.ll-ethylenedioxycamptothecin (1 g. 0.00239 mol) and isopropylamine (440 mg. 0.00744 mol) to give the desired product (703 mg. 56 %) as pale yellow solid. 1H NMR(DMSO d6) .δ:9.20(brs. 1H). 7.58 (s. 1H). 7.4 (s. 1H). 7.23 (s, 1H), 6.31 (m, 2H), 5.8 (m, 2H), 5.4 (s, 2H), 5.32 (s, 2H), 3.61~3.3(m,2H), 3.17-3.1 l(m,3H), 1.96-1.84 (m, 2H), 1.27 (d,6H, J=7.5Hz), 0.92(t, 3H, J=6.8Hz) Example 9: (S)-7-(2-(N-isopropylamino)ethyll-10,11- ethylenedioxycamptothecin hydrochloride The same procedure as in example 2 was applied to (S)-7-methyl-10,1 l-ethylenedioxycamptothecin (1 g, 0.00239 mol) and isopropylamine (440 mg, 0.00744 mol) to give the desired product (579 mg, 46 %) as pale yellow solid. The analysis data of the product is the same as example 8. Example 10: (S)-7-l2-(N-isopropylamino)ethyll-10,11- ethylenedioxycamptothecin hydrochloride The same procedure as in example 3 was applied to (S)-7- methyl-10,1 l-ethylenedioxycamptothecin (1 g, 0.00239 mol) and isopropylamine (440 mg, 0.00744 mol) to give the desired product (668 mg, 53 %) as pale yellow solid. The analysis data of the product is the same as example 8. Example 11: (S)-7-l2-(N-propylamino)ethyll-10,11- methylcncdioxycamptothecin hydrochloride The same procedure as in example 1 was applied to (S)-7-methyl-10,11-methylenedioxycamptothecin (1 g, 0.00248 mol) and propylamine (440 mg, 0.00744 mol) lo give the desired product (466 mg, 42%) as pale yellow solid. 1H NMR( DMSO-d6) δ : 7.6 (s, 1H), 7.38 (s, 1H), 7.21 (s, 1H), 6.26 (s, 2H), 5.4 (s, 2H), 5.29 (s, 2H), 3.56-3.31 (m, 2H), 3.18-3.03 (m, 4H), 1.91-1.81 (m, 2H), 1.29-1.04 (m, 8H), 0.87 (i, 3H, J=6.8Hz), 0.74(1, 3H,J=7.1 Hz) Example 12: (S)-7-[2-(N-propylamino)ethyl]-10,ll- ethylenedioxycamptothecin hydrochloride The same procedure as in example 1 was applied to (S)-7-methyl-10,11-ethylenedioxycamptothecin (1 g, 0.00239 mol) and propylamine (440 mg, 0.00744 mol) to give the desired product (575 mg, 46 %) as pale yellow solid. 1H NMR(DMSO-d6) δ : 7.6 (s, 1H), 7.36 (s, 1H), 7.20 (s, 1H), 6.26 (s, 2H), 5.81 (s, 2H), 5.41 (s, 2H), 5.28 (s, 2H), 3.52-3.41 (ra, 2H), 3.16-3.01 (m,4H), 1.93-1.79 (m, 2H), 1.28-1.02 (m, 8H), 0.88 (t, 3H, J=7.1Hz), 0.78 (t, 3H, J=7.1Hz) Example 13: (S)-7-[2-(N-isopropylbenzylamino)ethyl] camptothecin hydrochloride (S)-7-methylcamptothecin (8 g, 0.0221 mol), isopropyl-benzylamine (9.88 g, 0.0662 mol) and c-HCi (6.93 ml. 0.0684 mol) were added to dimethyl sulfoxide (80 ml). then. the same procedure as in example 1 was performed to gi\e the desired product [9.27g, 75 %) as pale yellow solid. 1H NMR ( DMSO-d6 400MHz) δ : 8.38 (d, 1H, J=8.5Hz), 8.13(d, 1H, J=8.5Hz), 7.86 (dd, 1H, J=8.5, 8.0Hz), 7.74 (dd, 1H, J=8.5, 8.0Hz), 7.52-7.31 (m, 5H), 7.29 (s, 1H), 6.52 (s, 1H), 5.43 (s, 2H), 5.35 (s, 2H), 3.66-3.59 (m, 2H), 3.54 (s, 2H), 3.45-3.34 (m, 1H), 3.21-3.16 (m,2H), 1.92-1.82 (m, 2H), 1.26 (d, 6H, J=6.4Hz), 0.88 (t, 3H, J=8.0Hz) Example 14: (S)-7-[2-(N-isopropylamino)ethyl] camptothecin hydrochlorid Pd-C (10%, 500 mg), 4.4% formic acid (10 ml) and methanol (100 ml) were added to (S)-7-[2-(N-isopropyl benzylamino)ethyl]camptothecin hydrochloride (5 g, 0.0089 mol) and the reaction mixture was stirred at room temperature for 18 hours. Then, the reaction solution was filtered and the filtrate, so obtained, was distilled under reduced pressure. The residue, so obtained, was purified by flash column chromatography (methylenechloride: methanol = 10: 1) to give the desired product (3.6 g, 86%) as pale yellow solid. The analysis data of the product is the same as example 1. The present invention relates to a process of manufacturing camptothecin derivatives or pharmaceulically acceptable salts thereof Especially. 7-substituted campiothecin derivatises that have excellent antineoplastic activities can be manufactured easily and economilcally through the said process. CLAIMS: 1. A process of manufacturing camptothecin derivatives of the compound of general formula 1 or a pharmaceutically acceptable salt thereof, wherein the said process comprises; - reacting a compound of formula 2 with an -amine or salt thereof and with a formaldehyde source of the kind as herein described in the presence of an acid and a reaction solvent at a temperature ranging between 20-1 sec. (Formula Removed) - wherein Y and Z are the same or different and each represents a hydrogen atom, an C1 - C6 alkyl group, a C1 C3 hydroxyalkyl group, or a general protecting group of amine such as benzyloxycarbonyl, benzyl, etc.; R1 is a hydrogen atom, an C1- C6 alkyl group, or a hydroxy group; R2 and R3 are the same or different and each represents a hydrogen atom or a hydroxy group, or they may be attached together to form a cyclic moiety, which is methylenedioxy or an ethylenedioxy group; - R4 is a hydrogen atom or an C1 - C6 alkyl group; and - R5 is hydrogen, hydroxy, fluoro, chloro, bromo, iodo or amine. 2. A process as claimed in claim 1 wherein R1, R2, R3, R4, R5 and Y are the same and each represents a hydrogen atom; and Z is isopropyl. 3. A process as claimed in claim 1 or 2, wherein the said formaldehyde source is formalin solution, paraformaldehyde, trioxane or dimethyl sulfoxide. 4. A process as claimed in claim 1 or 2 wherein the said amine is methyl amine, ethyle amine, propyl amine, isopropyl amine, butyl amine, pentyl amine, hexyl amine, benzyl amine, isopropylbenzyl amine, dimethyl amine, diethyl amine, benzyloxycarbonyl amine, hydroxymethyl amine, hydroxyethyl amine or hydroxyropyl amine. 5. A process as claimed in claim 1 or 2, wherein said reaction solvent is water, methanol, ethanol, dioxane, acetic acid, dimethylformamide or dimethyl sulfoxide; the said acid is hydrochloric acid, sulfuric acid, acetic acid, phosphoric acid, p-toluenesulfonic acid, methanesulfonic acid, tifluoromethanesulfonic acid, boron trifluroide or tin chloride; 6. A process of manufacturing the compound of general formula 1 or a pharmaceutically acceptable salt thereof substantially as herein described with reference to the foregoing examples.

Documents:

1921-del-1998-abstract.pdf

1921-del-1998-claims cancelled.pdf

1921-del-1998-claims.pdf

1921-del-1998-complete specification(granted).pdf

1921-del-1998-correspondence-others.pdf

1921-del-1998-correspondence-po.pdf

1921-del-1998-description (complete).pdf

1921-del-1998-form-1.pdf

1921-del-1998-form-2.pdf

1921-del-1998-form-3.pdf

1921-del-1998-form-6.pdf

1921-del-1998-form-9.pdf

1921-del-1998-pa.pdf

abstract.jpg